172 related articles for article (PubMed ID: 9818841)
1. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies.
Fueyo J; Gomez-Manzano C; Yung WK; Kyritsis AP
Neurology; 1998 Nov; 51(5):1250-5. PubMed ID: 9818841
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations of p53 but not p16/CDKN2 or PTEN/MMAC1 tumor suppressor genes predispose to gliomas. The ANOCEF Group. Association des NeuroOncologues d'Expression Française.
Zhou XP; Sanson M; Hoang-Xuan K; Robin E; Taillandier L; He J; Mokhtari K; Cornu P; Delattre JY; Thomas G; Hamelin R
Ann Neurol; 1999 Dec; 46(6):913-6. PubMed ID: 10589545
[TBL] [Abstract][Full Text] [Related]
3. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
4. Targeting in gene therapy for gliomas.
Fueyo J; Gomez-Manzano C; Yung WK; Kyritsis AP
Arch Neurol; 1999 Apr; 56(4):445-8. PubMed ID: 10199333
[TBL] [Abstract][Full Text] [Related]
5. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
6. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Ishii N; Maier D; Merlo A; Tada M; Sawamura Y; Diserens AC; Van Meir EG
Brain Pathol; 1999 Jul; 9(3):469-79. PubMed ID: 10416987
[TBL] [Abstract][Full Text] [Related]
7. Molecular abnormalities and correlations with tumor response and outcome in glioma patients.
Pollack IF; Hamilton RL; Finkelstein SD; Lieberman F
Neuroimaging Clin N Am; 2002 Nov; 12(4):627-39. PubMed ID: 12687916
[TBL] [Abstract][Full Text] [Related]
8. Functional evaluation of p53 and PTEN gene mutations in gliomas.
Kato H; Kato S; Kumabe T; Sonoda Y; Yoshimoto T; Kato S; Han SY; Suzuki T; Shibata H; Kanamaru R; Ishioka C
Clin Cancer Res; 2000 Oct; 6(10):3937-43. PubMed ID: 11051241
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas.
Fults D; Pedone C
Neuro Oncol; 2000 Apr; 2(2):71-9. PubMed ID: 11303623
[TBL] [Abstract][Full Text] [Related]
10. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.
Furnari FB; Lin H; Huang HS; Cavenee WK
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12479-84. PubMed ID: 9356475
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.
James CD; Galanis E; Frederick L; Kimmel DW; Cunningham JM; Atherton-Skaff PJ; O'Fallon JR; Jenkins RB; Buckner JC; Hunter SB; Olson JJ; Scheithauer BW
Int J Oncol; 1999 Sep; 15(3):547-53. PubMed ID: 10427138
[TBL] [Abstract][Full Text] [Related]
12. Translational research strategies applied to glioma therapeutics.
Berger MS; Keles GE
Clin Neurosurg; 2004; 51():203-6. PubMed ID: 15571146
[No Abstract] [Full Text] [Related]
13. Biological mechanisms of glioma invasion and potential therapeutic targets.
Tysnes BB; Mahesparan R
J Neurooncol; 2001 Jun; 53(2):129-47. PubMed ID: 11716066
[TBL] [Abstract][Full Text] [Related]
14. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli.
Abe T; Terada K; Wakimoto H; Inoue R; Tyminski E; Bookstein R; Basilion JP; Chiocca EA
Cancer Res; 2003 May; 63(9):2300-5. PubMed ID: 12727853
[TBL] [Abstract][Full Text] [Related]
15. PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis.
Izumoto S; Ohnishi T; Kanemura H; Arita N; Maruno M; Moriuchi T; Suzuki S; Yoshimine T
J Neurooncol; 2001 May; 53(1):21-6. PubMed ID: 11678426
[TBL] [Abstract][Full Text] [Related]
16. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas.
Maier D; Zhang Z; Taylor E; Hamou MF; Gratzl O; Van Meir EG; Scott RJ; Merlo A
Oncogene; 1998 Jun; 16(25):3331-5. PubMed ID: 9681833
[TBL] [Abstract][Full Text] [Related]
17. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Su JD; Mayo LD; Donner DB; Durden DL
Cancer Res; 2003 Jul; 63(13):3585-92. PubMed ID: 12839945
[TBL] [Abstract][Full Text] [Related]
18. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH; Hu R; Lin H; Davis T; Iliev D; Frye C; Swedlund B; Hansen KL; Vinson VL; Gumpper KL; Ellis L; El-Naggar A; Frazier M; Jasser S; Langford LA; Lee J; Mills GB; Pershouse MA; Pollack RE; Tornos C; Troncoso P; Yung WK; Fujii G; Berson A; Steck PA
Cancer Res; 1997 Dec; 57(23):5221-5. PubMed ID: 9393738
[TBL] [Abstract][Full Text] [Related]
19. [Molecular control of the cellular cycle and apoptosis: new treatments for gliomas].
Fueyo J; Gómez-Manzano C
Neurologia; 1998; 13(7):349-55. PubMed ID: 9810797
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeting for malignant gliomas (Review).
Kondo Y; Hollingsworth EF; Kondo S
Int J Oncol; 2004 May; 24(5):1101-9. PubMed ID: 15067331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
